ORBIMED ADVISORS LLC
Q4 2024 Form 13-F

NEW YORK, NEW YORK
CIK 0001055951 · CRD 118608 · SEC-registered investment adviser
Consolidated report · includes 1 manager since Q2 2013
$4.8B Reported Value Total

ORBIMED ADVISORS LLC reports 31 total accounts under management (AUM). There are 31 discretionary accounts valued at $17,339,330,000, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Private funds (Form ADV)
34 funds · $22.1B gross asset value
Other: $13.5B · Hedge Fund: $4.3B · Private Equity Fund: $4.3B
Source: Form ADV filed 2026-08-18
Reported value
$4.8B
Quarter over quarter
-8.0%
Holdings
110
Top-10 concentration
44.4%

Filing Structure

Reports holdings for

Key People

Form ADV owners & control persons
Carl Lee Gordon
MEMBER
Geoffrey Che-Chang Hsu
MEMBER
William Carter Neild
MEMBER

Filing Navigation

13F Metrics

Loading 13F Metrics

Q4 2024 13F record

Q4 2024 13F filing summary

Q4 2024 Form 13F portfolio summary
Period of report December 31, 2024
Filed February 14, 2025
Form 13F-HR
Reported value $4.8B
Positions 110
Change in reported value -11.6%
New positions 20
Exited positions 18
Position turnover 29.7%
Top-10 concentration 44.4%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q2 2026 13F
Filed Aug 14, 2026
116 $5.4B
Q1 2026 13F
Filed May 15, 2026
104 $5.0B
Q4 2025 13F
Filed Feb 17, 2026
103 $4.9B
Q3 2025 13F
Filed Nov 14, 2025
97 $4.2B
Q2 2025 13F
Filed Aug 14, 2025
96 $4.0B
Q1 2025 13F
Filed May 15, 2025
105 $4.2B
Q4 2024 13F
Filed Feb 14, 2025
110 $4.8B
Q3 2024 13F
Filed Nov 14, 2024
108 $5.5B
Q2 2024 13F
Filed Aug 14, 2024
107 $5.0B
Q1 2024 13F
Filed May 15, 2024
111 $5.4B
Q4 2023 13F
Filed Feb 14, 2024
108 $5.0B
Q3 2023 13F
Filed Nov 14, 2023
119 $4.7B
Q2 2023 13F
Filed Aug 14, 2023
117 $5.5B
Q1 2023 13F
Filed May 15, 2023
113 $5.0B
Q4 2022 13F
Filed Feb 14, 2023
111 $5.2B
Q3 2022 13F
Filed Nov 14, 2022
125 $5.3B
Q2 2022 13F
Filed Aug 15, 2022
133 $5.5B
Q1 2022 13F
Filed May 16, 2022
136 $6.1B
Q4 2021 13F
Filed Feb 14, 2022
154 $7.6B
Q3 2021 13F
Filed Nov 15, 2021
165 $8.8B

33 earlier quarters on file — choose one from the quarter menu above.

Top 20 holdings · Q4 2024

Largest Q4 2024 13F positions by reported value
# Holding Reported value % of portfolio
1 EWTX EDGEWISE THERAPEUTICS INC $401.1M 8.28%
2 SVA SINOVAC BIOTECH LTD $334.0M 6.9%
3 BSX BOSTON SCIENTIFIC CORP $282.3M 5.83%
4 LLY ELI LILLY & CO $260.6M 5.38%
5 ISRG INTUITIVE SURGICAL INC $209.7M 4.33%
6 ELVN ENLIVEN THERAPEUTICS INC $179.1M 3.7%
7 NBIX NEUROCRINE BIOSCIENCES INC $128.1M 2.64%
8 SYK STRYKER CORPORATION $124.0M 2.56%
9 SRPT SAREPTA THERAPEUTICS INC $117.1M 2.42%
10 ARGX ARGENX SE $116.7M 2.41%
11 IRON DISC MEDICINE INC $113.2M 2.34%
12 THC TENET HEALTHCARE CORP $100.0M 2.06%
13 IONS IONIS PHARMACEUTICALS INC $98.5M 2.03%
14 ALNY ALNYLAM PHARMACEUTICALS INC $97.8M 2.02%
15 UPB UPSTREAM BIO INC $93.6M 1.93%
16 SPRY ARS PHARMACEUTICALS INC $87.4M 1.81%
17 EW EDWARDS LIFESCIENCES CORP $84.8M 1.75%
18 MRK MERCK & CO INC $82.6M 1.7%
19 AVBP ARRIVENT BIOPHARMA INC $80.6M 1.67%
20 BIIB BIOGEN INC $77.9M 1.61%

Values as reported on the Q4 2024 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings